每周给予 30000IU 红细胞生成素-β治疗同期放化疗胃肠道肿瘤患者贫血的疗效。
Efficacy of epoetin-beta 30,000 IU/week in correcting anaemia in patients with gastrointestinal tumours subjected to concomitant chemoradiotherapy.
机构信息
Servicio de Oncología Radioterápica, Hospital Clínico Universitario Santiago de Compostela, Travesía Choupana, s/n, ES-15706 Santiago de Compostela, La Coruña, Spain.
出版信息
Clin Transl Oncol. 2010 Dec;12(12):843-8. doi: 10.1007/s12094-010-0607-4.
OBJECTIVE
The aim of the project was to assess the effectiveness and safety of weekly epoetin-beta (EB) in patients with gastrointestinal cancer (GIC) subjected to concomitant chemoradiotherapy (CCTRT).
METHODS
In this clinical prospective and multicentre cohort study EB was administered at a dose of 30,000 IU/ week, during CCTRT and in the four weeks thereafter, and suspended if haemoglobin (Hb) increased >2 g/dl or Hb >12-13 g/dl. Effectiveness was defi ned as Hb increase ≥1 g/dl vs. baseline. Time to response, treatment toxicity and transfusion requirements were also assessed.
RESULTS
EB was effective in 75.8% of the evaluable population within a median of four weeks from EB initiation, without blood transfusions. Over 80% of all patients remained below the threshold (Hb ≤13 g/dl) and no study drug-related adverse reactions were recorded.
CONCLUSION
Weekly EB proved to be effective and well tolerated by patients with GIC subjected to CCTRT.
目的
本项目旨在评估胃肠道癌（GIC）患者同步放化疗（CCTRT）期间每周接受促红细胞生成素-β（EB）治疗的有效性和安全性。
方法
在这项前瞻性、多中心队列研究中，在 CCTRT 期间和之后的四周内，给予 EB 剂量为 30000IU/周，如果血红蛋白（Hb）升高超过 2g/dl 或 Hb 升高超过 12-13g/dl，则暂停给药。有效性定义为 Hb 增加≥1g/dl 与基线相比。还评估了反应时间、治疗毒性和输血需求。
结果
在 EB 开始后中位数为四周内，可评估人群中 75.8%的患者有效，且无需输血。超过 80%的患者 Hb 仍低于阈值（Hb≤13g/dl），且未记录到任何与研究药物相关的不良反应。
结论
每周 EB 对接受 CCTRT 的 GIC 患者有效且耐受良好。
Zotero 插件